Anthropic's Long-Term Benefit Trust appoints Vas Narasimhan to Board of Directors
Summary
Anthropic's Long-Term Benefit Trust appoints Vas Narasimhan to the Board of Directors, strengthening efforts toward the safe development of AI and the pursuit of the public good.
Key Points
- Vas Narasimhan has been appointed to the Board of Directors by Anthropic's Long-Term Benefit Trust.
- He is the CEO and physician-scientist at Novartis, and believes AI holds tremendous potential in healthcare and life sciences.
- Anthropic co-founder Daniela Amodei emphasized that Narasimhan has exceptional experience in deploying new technologies safely and at scale.
- The Long-Term Benefit Trust plays a role in balancing Anthropic's financial success with its public benefit mission, and with this appointment, Trust-nominated directors now hold a majority on the board.
Notable Quotes & Details
Notable Data / Quotes
- "Vas brings something rare to our board. He's overseen the development and approval of more than 35 novel medicines for the benefit of patients around the world in one of the most regulated industries." - Daniela Amodei, Co-founder and President of Anthropic.
- "The Long-Term Benefit Trust's role is to appoint directors who will ensure Anthropic responsibly balances its commitment to stockholders and its public benefit mission as the company grows. Vas has spent his career stewarding breakthrough science responsibly —exactly the perspective we are excited to have on the board as we develop consequential technology. We're excited for what he'll bring to the table," - Neil "Buddy" Shah, Chair of Anthropic's Long-Term Benefit Trust.
Intended Audience
AI industry professionals, investors, corporate executives